USA - NASDAQ:HOLX - US4364401012 - Common Stock
The current stock price of HOLX is 74.03 USD. In the past month the price increased by 8.34%. In the past year, price decreased by -10.23%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.81 | 215.50B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.97 | 194.36B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.56 | 146.70B | ||
| SYK | STRYKER CORP | 27.14 | 136.67B | ||
| MDT | MEDTRONIC PLC | 16.22 | 115.05B | ||
| BDX | BECTON DICKINSON AND CO | 12.39 | 50.66B | ||
| IDXX | IDEXX LABORATORIES INC | 59.69 | 57.35B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.5 | 49.03B | ||
| RMD | RESMED INC | 25.01 | 36.13B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.09 | 33.73B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.61 | 26.55B | ||
| STE | STERIS PLC | 24.81 | 23.31B |
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. The company is headquartered in Marlborough, Massachusetts and currently employs 7,063 full-time employees. The firm is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.
HOLOGIC INC
250 Campus Drive
Marlborough MASSACHUSETTS 01752 US
CEO: STEPHEN P. MACMILLAN
Employees: 7063
Phone: 15082632900
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. The company is headquartered in Marlborough, Massachusetts and currently employs 7,063 full-time employees. The firm is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.
The current stock price of HOLX is 74.03 USD. The price increased by 0.16% in the last trading session.
HOLX does not pay a dividend.
HOLX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
HOLOGIC INC (HOLX) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
HOLOGIC INC (HOLX) has a market capitalization of 16.47B USD. This makes HOLX a Large Cap stock.
You can find the ownership structure of HOLOGIC INC (HOLX) on the Ownership tab.
ChartMill assigns a technical rating of 7 / 10 to HOLX. When comparing the yearly performance of all stocks, HOLX is a bad performer in the overall market: 65.49% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to HOLX. HOLX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Over the last trailing twelve months HOLX reported a non-GAAP Earnings per Share(EPS) of 4.15. The EPS increased by 4.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.79% | ||
| ROA | 6.33% | ||
| ROE | 11.5% | ||
| Debt/Equity | 0.52 |
27 analysts have analysed HOLX and the average price target is 75.7 USD. This implies a price increase of 2.25% is expected in the next year compared to the current price of 74.03.
For the next year, analysts expect an EPS growth of 6.03% and a revenue growth 1.61% for HOLX